Wall Street consensusAverage target 7.00 USD+75.0%
You have reached the limit of 3 free reports this month
Subscribe to access the complete report for Oramed Pharmaceuticals Inc: quant scores, valuation history, consensus estimates, peers and six years of financial statements.
Income statement, Oramed Pharmaceuticals Inc, fiscal years, most recent first
2025
2024
2023
2022
2021
2020
Total revenue
2.0
0
1.3
2.7
0.9
2.7
Cost of revenue
2.0
–
–
–
–
0
Gross profit
0
0
1.3
2.7
0.9
2.7
Selling, general & administrative expenses
8.7
6.5
8.4
15.7
4.2
4.2
Research & development
6.4
6.3
9.0
27.6
9.0
10.2
Interest expense (income), operating
–
–
–
–
–
–
Unusual expense (income)
–
–
–
–
–
–
Other operating expenses
0
0
−0.3
0
0
0
Operating income
−15.1
−12.8
−15.8
−40.6
−12.3
−11.8
Net interest income (expense)
90.3
−4.1
22.3
2.8
0.1
0.3
Gain (loss) on sale of assets
–
–
–
–
–
–
Other non-operating income (expense)
0.1
1.0
−1.4
0.2
0
0
Net income before taxes
75.3
−15.9
5.1
−37.7
−12.3
−11.5
Provision for taxes
11.3
3.2
0
0.1
–
0
Minority interest
0
0
0.4
1.2
0.6
–
Equity in affiliates
–
–
–
–
–
–
U.S. GAAP adjustment
–
–
–
–
–
–
Net income before extraordinary items
64.0
−19.1
5.5
−36.6
−11.7
−11.5
Extraordinary items
–
–
–
–
–
–
Net income
64.0
−19.1
5.5
−36.6
−11.7
−11.5
EBIT, normalized
−15.1
−12.8
−15.8
−40.6
−12.3
−11.8
EBITDA, normalized
−15.0
−12.6
−15.6
−40.5
−12.3
−11.8
Basic EPS, normalized
1.50
−0.48
0.14
−0.94
−0.31
–
Balance sheet in millions of USD, fiscal years
Balance sheet, Oramed Pharmaceuticals Inc, fiscal years, most recent first
2025
2024
2023
2022
2021
2020
Assets
Cash & short-term investments
126
142
162
156
146
39.9
Receivables
–
–
–
–
–
–
Total inventory
–
–
–
–
–
–
Prepaid expenses
2.7
1.3
0.5
1.4
1.7
0.6
Other current assets
4.6
0
0
0
0
0
Total current assets
133
143
163
157
148
40.5
Property, plant & equipment
1.3
1.1
1.6
1.8
0.9
0.2
Goodwill
–
–
–
–
–
–
Intangibles
–
–
–
–
–
–
Long-term investments
90.7
10.9
56.4
2.7
29.0
3.9
Note receivable
–
–
–
–
–
–
Other long-term assets
5.6
0
0
0
0
0
Total assets
231
155
221
162
178
44.6
Liabilities
Accounts payable
0.4
0.8
0.6
2.2
–
0.6
Payable/accrued
–
–
–
–
4.5
–
Accrued expenses
2.8
1.4
1.3
2.2
0.1
1.1
Short-term debt
0
0
51.0
0
0
0
Current portion of long-term debt
–
–
–
–
–
–
Other current liabilities
15.9
3.5
0.3
1.4
2.7
2.8
Total current liabilities
19.1
5.7
53.2
5.7
7.4
4.5
Long-term debt
0
0
0
0
0
0
Minority interest
0
−0.9
−0.9
−0.7
0.2
–
Other liabilities
12.0
4.2
4.4
4.7
3.8
7.2
Total liabilities
31.1
9.0
56.7
9.8
11.4
11.8
Shareholders' equity
Preferred stock
–
–
–
–
–
–
Common stock
0.5
0.5
0.5
0.5
0.5
0.3
Additional paid-in capital
323
322
321
314
293
125
Retained earnings (accumulated deficit)
−123
−177
−158
−163
−127
−92.6
Treasury stock
–
–
–
–
–
–
Other equity
0
0
0
0
0
0
Total equity
200
146
164
152
166
32.9
Total liabilities & shareholders' equity
231
155
221
162
178
44.6
Cash flow statement in millions of USD, fiscal years
Cash flow statement, Oramed Pharmaceuticals Inc, fiscal years, most recent first
2025
2024
2023
2022
2021
2020
Operating activities
Net income
64.0
−19.1
5.1
−37.8
−12.3
−11.5
Depreciation, depletion & amortization
0.1
0.2
0.2
0.1
0
0
Deferred taxes
7.9
–
–
–
–
–
Non-cash items
−79.3
7.3
−12.9
10.7
1.8
2.2
Changes in working capital
−1.9
3.2
−2.7
−0.9
−0.7
−3.2
Cash from operations
−9.1
−8.4
−10.3
−27.9
−11.1
−12.4
Investing activities
Capital expenditures
0
0
−0.3
−0.5
0
−0.1
Other investing cash flows
5.5
106
−72.8
30.7
−99.2
4.7
Cash from investing
5.4
106
−73.0
30.2
−99.2
4.6
Financing activities
Financing cash flow items
–
0
–
−0.8
–
–
Cash dividends paid
–
–
–
–
–
–
Issuance (retirement) of debt, net
–
–
–
–
–
–
Other financing cash flows
−4.7
−52.0
52.0
11.6
60.6
23.8
Cash from financing
−4.7
−52.0
52.0
10.8
60.6
23.8
Foreign exchange effects
0
0
−0.1
−0.1
0
0
Net change in cash
−8.5
45.4
−31.4
13.0
−49.8
16.0
Free cash flow
−9.2
−8.4
−10.5
−28.4
−11.1
−12.5
Disclaimer
The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.
This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.
QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.
Live quote provided by TradingView. Report data updated Nov 2, 2026 after market close.